Cardiometabolic Risk Summit
Courses and Conferences
Our Cardiometabolic Risk Summit 2018 wrapped up this Sunday with a plethora of educational sessions. Couldn’t make the trip? Catch up with our news coverage!
In light of the current hypertension epidemic, Florian Rader, MD, advised about distinguishing resistant hypertension from mimics and described the latest treatment options, as well as those on the horizon.
The 2017 AHA/ACC hypertension guidelines will likely change how most physicians measure and manage BP, said Dr F. Wilford Germino at CRS 2018.
James A. Underberg, MD, outlined recent cardiovascular outcomes evidence for PCSK9 inhibitors and discussed strategies for improving access to therapy for appropriate patients.